Find a Doctor

Dr. John T Kissel

Ohio State University Hospitals
Psychiatry, Neurology

Bio


John Kissel is a Psychiatrist and a Neurologist in Columbus, Ohio. Dr. Kissel is a global expert in Spinal Muscular Atrophy Type 3. He has been an author on 123 peer reviewed articles in the past 15 years. In particular, he has been an author on 13 peer reviewed articles regarding Spinal Muscular Atrophy Type 3. Dr. Kissel's top three areas of expertise are Spinal Muscular Atrophy Type 3, Myasthenia Gravis, Paramyotonia Congenita, and Spinal Muscular Atrophy. He is licensed to treat patients in OH.

Contact

2050 Kenny Rd
7th Floor
Columbus, OH 43221, US

Latest Advances


  • Condition: Myasthenia Gravis
  • Journal: Neurology
  • Treatment Used: Thymectomy
  • Number of Patients: 0
  • Published —
The study researched the outcomes of prednisone withdrawal in patients with myasthenia gravis.
  • Condition: Inclusion Body Myositis
  • Journal: The Lancet. Neurology
  • Treatment Used: Intravenous Bimagrumab
  • Number of Patients: 63
  • Published —
This study assessed the safety, effectiveness, and tolerability of bimagrumab in patients with inclusion body myositis.
  • Condition: Non-thymomatous myasthenia gravis
  • Journal: The Lancet. Neurology
  • Treatment Used: Thymectomy plus prednisone versus prednisone alone
  • Number of Patients: 111
  • Published —
The study researched the use of thymectomy plus prednisone versus prednisone alone for patients with non-thymomatous myasthenia gravis.
  • Condition: Spinal Muscular Atrophy
  • Journal: Pediatric pulmonology
  • Treatment Used: AVXS-101 Gene Replacement Therapy
  • Number of Patients: 12
  • Published —
This study tested the safety and efficacy of using AVXS-101 gene replacement therapy to treat patients with spinal muscular atrophy.
  • Condition: Patients with Spinal and Bulbar Muscular Atrophy
  • Journal: The Lancet. Neurology
  • Treatment Used: IGF-1 Mimetic
  • Number of Patients: 31
  • Published —
This study assessed safety, tolerability, and preliminary effectiveness of BVS857, an IGF-1 mimetic, in patients with spinal and bulbar muscular atrophy.
  • Condition: Atrophy type I
  • Journal: Muscle & nerve
  • Treatment Used: L-carnitine and valproic acid (VPA)
  • Number of Patients: 37
  • Published —
This study evaluated the effects of infant atrophy type I, specifically muscular atrophy (SMA).

Clinical Trials


Contact

2050 Kenny Rd
7th Floor
Columbus, OH 43221, US

Credentials

  • Licenses
    Psychiatry & Neurology in OH

Insurance

Contact them to find out if they accept your insurance plan.